RECURRENT CUTANEOUS MELANOMA
Clinical trials for RECURRENT CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for RECURRENT CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough melanoma? drug targets Cancer's growth signals
Disease control OngoingThis study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal was to see if the drug could shrink tumors, and researchers also loo…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:41 UTC
-
New immunotherapy shows promise in preventing melanoma return
Disease control OngoingThis study tested whether the drug pembrolizumab works better than current standard treatments (high-dose interferon or ipilimumab) in preventing melanoma from coming back after surgery. Over 1,300 patients with high-risk stage III or IV melanoma that had been removed took part. …
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:33 UTC
-
New combo aims to shrink melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with melanoma that can be surgically removed. About 60 adults with stage III melanoma will receive treatment before surgery to see if…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC